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Background
As a clinical setting in which local live biological therapy
is already well established, nonmuscle invasive bladder
cancer (NMIBC) presents intriguing opportunities for
oncolytic virotherapy. Coxsackievirus A21 (CVA21) is a
novel intercellular adhesion molecule-1 (ICAM-1) tar-
geted immunotherapeutic virus. Combining CVA21 with
low doses of chemotherapy (Mitomycin C) enhances
CVA21 viral replication and oncolysis by increasing
expression levels of ICAM1 on bladder cancer cells. As
well as initiating oncolysis, oncolytic viruses can also
induce immunogenic cell death (ICD) determinants
which is thought to be the optimal way to trigger a
tumour-specific response and crucial for long-term ther-
apeutic success. This study set out to confirm the
enhanced cytotoxicity in vitro of bladder cancer cell
lines and tissues following combined treatment of mito-
mycin C and CVA21 and to demonstrate the induction
of immunogenic cell death determinants.
Methods
Characterization of CVA21 cytotoxicity in a panel of
6 bladder cancer cell lines yielded a range of sensitivities.
CVA21 cytotoxicity largely correlated with expression of
the viral receptor ICAM-1. CAV21 in combination with
Mitomycin C resulted in up-regulation of ICAM-1 and
significantly increased cytotoxicity over CVA21 alone.
Furthermore, CVA21 induced the expression of multiple
ICD determinants (calreticulin, ATP and HMGB1 release)
and the immunogenic cell marker, Fas, associated with
susceptibility to immune attack. The expression of these
immunogenic markers was up-regulated in the CVA21
and combination treated cells as compared to Mitomycin
C only and untreated cells. The caspase-glow 3/7 assay
revealed apoptosis as the primary mode of death. This was
further confirmed with the use of an apoptotic inhibitor
(Z-VAD-FMK) which significantly inhibited cell-death of
CVA21 infected cells.
Results
The above data provided the rationale for a two stage
Phase I study in which patients with NMIBC receive
neoadjuvant CVA21 or low dose Mitomycin C plus
CVA21 prior to routine surgical removal (TURBT). The
Phase I/II CANON (CAVATAK in NONMuscle invasive
bladder cancer: NCT02316171) study investigating the tol-
erance of multiple escalating intravesicular doses of
CVA21 has shown general tolerance of the intravesicular
CVA21 treatment. Serial photography has identified possi-
ble evidence of viral induced surface haemorrhage and
inflammation of the tumour micro-environment. Potential
multicycle virus replication within the tumour was high-
lighted by detection of secondary viral load peaks in the
urine as evidenced by RTPCR and infectious TCID50
assays.
Conclusions
TURBT tissue analysis displayed marked tumour specific
cytoplasmic viral protein expression and widespread evi-
dence of viral-induced apoptotic cell death.
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